ArticleNagoya journal of medical science2026
Methotrexate and glucocorticoid use in relation to cross-sectional and longitudinal associations of red blood cell distribution width in patients with rheumatoid arthritis.
Article in Nagoya journal of medical science, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the clinical characteristics of red blood cell distribution width (RDW) in rheumatoid arthritis (RA) and the impact of treatment, including longitudinal dose changes. Among 691 RA patients enrolled in 2025, 591 with RDW recorded in both 2024 and 2025 were analyzed. Based on 2024 data, patients were classified into normal RDW (≤14.5%, n = 436) and high RDW (>14.5%, n = 155) groups. Logistic regression identified factors associated with high RDW. Associations with methotrexate (MTX) and glucocorticoid (GC) dose were examined, and one-year changes in RDW (ΔRDW, 2024-2025) were evaluated according to dose modifications. Patients with high RDW were older (70.6 vs 68.0 years), frequently used MTX (71.0% vs 57.6%) and GCs (41.3% vs 18.8%), had higher Disease Activity Score in 28 joints based on erythrocyte sedimentation rate (DAS28-ESR, 2.92 vs 2.68) and Health Assessment Questionnaire Disability Index (HAQ-DI, 0.64 vs 0.40), and lower hemoglobin (11.8 vs 12.9 g/dL). Multivariable analysis revealed that low hemoglobin (odds ratio [OR], 0.56), MTX use (OR, 2.47), and GC use (OR, 2.21) were independently associated with high RDW. The prevalence of high RDW increased with higher MTX (14.0%, 18.3%, 28.6%) and GC (14.0%, 20.7%, 43.2%) doses. Longitudinally, ΔRDW rose with MTX initiation or escalation (0.43 ± 0.91 vs -0.08 ± 1.06 or -0.26 ± 1.18), whereas GC changes were not significant. These findings indicate that RDW in RA is influenced more by treatment-particularly MTX use and dose escalation-than by inflammation. GC use also showed cross-sectional associations, though longitudinal effects were less evident. RDW should be interpreted in light of treatment rather than as a simple marker of disease activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.